Chordoid glioma of the third ventricle is considered to be a benign glial tumor located exclusively in the mid-anterior portion of the third ventricle near the hypothalamus and optic nerves, with the histological features of a chordoma and immuno-labeling for glial fibrillary acidic protein. Unfortunately, the clinical outcome of chordoid glioma has been poor, even in patients receiving gross total or partial removal with or without radiotherapy. Three cases of chordoid glioma of the third ventricle were treated with less invasive microsurgery for pathological diagnosis or partial removal without neuro-endocrinological complication, followed by gamma knife radiosurgery using a lower marginal dose for the optic nerves and hypothalamus. Gamma knife radiosurgery was performed after open biopsy in two patients, and after partial removal in the third patient using a lower marginal dose of 10.5 to 12 Gy. Serial magnetic resonance imaging revealed gradual decrease or at least no change in the tumor size, without significant complication at follow up 70 and 66 months later in two cases. The third patient accidentally died 13 months after gamma knife treatment. We conclude that low dose gamma knife radiosurgery after less invasive microsurgery is both safe and effective for the control of chordoid glioma of the third ventricle over a very long follow-up period.
Introduction
Chordoid glioma is a rare brain tumor first described among eight cases as a new clinico-pathological entity arising exclusively in the third ventricle of middle-aged females, 3) although one pediatric case was also reported. 7) A total of 55 cases have been reported so far ( Table 1 ). The pathological appearances of those cases were remarkably uniform. Chordoid glioma incorporates clusters and cords of epithelioid cells with eosinophilic cytoplasm, and prominent lymphoplasmacytic infiltrate. The stroma consists of a basophilic, often vacuolated, mucin-like matrix. Immunohistochemically, the tumor shows strong, diffuse reactivity for glial fibrillary acidic protein (GFAP) and vimentin, and focal or negative reactivity for epithelial membrane antigen (EMA) and cytokeratins. The origin of chordoid glioma is not well understood. The World Health Organization (WHO) classification of brain tumors in 2007 included chordoid glioma in the category of``other neuroepithelial tumors.'' Although clinicopathological findings have been accumulated and extensively studied, the treatment methods and clinical outcomes of chondroid glioma are not well established.
We describe three cases of third ventricular chordoid glioma with special emphasis on the effects of planned microsurgery and lower dose stereotactic radiosurgery as a tentative approach.
Case Reports
Three pathologically verified cases of chordoid glioma of the third ventricle were identified by open biopsies in two patients and partial removal by craniotomy in a third patient. Residual tumors after less invasive surgery were Yellow lines indicate the 50% isodose line precisely covering the tumor margins. Green lines indicate optic nerves (OPN). Case 1 had a tumor volume of 2.9 ml and was treated with a marginal dose of 11 Gy, with the dose to the optic nerve of less than 7.5 Gy. Case 2 had a tumor volume of 6.4 ml and was treated with a marginal dose of 10.5 Gy, with the dose to the optic nerve of less than 8.0 Gy. Case 3 had a tumor volume of 4.4 ml and was treated with a marginal dose of 12 Gy, with the dose to the optic nerve of less than 10 Gy.
Neurol Med Chir (Tokyo) 53, April, 2013 (Fig. 1) . Carotid angiography detected no tumor stain or abnormal vessels. Bifrontal craniotomy was performed on December 22, 2003 , and biopsy of the tumor through the lamina-terminalis revealed intraventricular meningioma, which was corrected to chordoid glioma based on immunohistochemical and electron microscopy findings. The postoperative course was uneventful except for a minor subfrontal hematoma, which resolved within 2 weeks, and she was discharged. The patient was referred to Nagoya Radiosurgery Center for gamma knife radiosurgery. The tumor was 15.5 × 19 × 19.9 mm with a volume of 2.9 ml, which was treated with a maximal dose of 22 Gy and a marginal dose of 11 Gy, with the dose to the optic nerve of less than 7.5 Gy, on April 23, 2004 ( Fig. 2A) . The tumor was unchanged as observed by MR imaging at 66 months (Fig. 3A, B) , and the patient has been followed up for more than 70 months after gamma knife surgery without general or neurological abnormality. Case 2: A 31-year-old woman had shown deterioration of her myopia for the last 2 years. Head MR imaging detected a suprasellar mass with a cyst. She was admitted to the Department of Neurosurgery, Nagoya University Hospital. Removal of the tumor was attempted through a bifrontal craniotomy on April 5, 2004 . The solid tumor could not be removed through the lamina terminalis because of its close proximity to the short anterior communicating artery, and also because the tumor tightly ad- hered to the hypothalamus. Finally, cyst evacuation and biopsy of the tumor were performed. The diagnosis based on frozen section examination was plasmacyte-rich meningioma, which was corrected to chordoid glioma after immunohistochemical and electron microscopy studies. Her visual acuity improved after decompression of the optic nerves resulting from cyst evacuation. She was referred to the Nagoya Radiosurgery Center for gamma knife radiosurgery of the residual tumor. The mean diameter and volume of the tumor were 22.7 mm and 6.4 ml, respectively. The tumor was treated by gamma knife radiosurgery with a maximum dose of 21.0 Gy and marginal dose of 10.5 Gy on June 4, 2004 (Fig. 2B) . The patient has been followed up for more than 66 months after the gamma knife surgery, and was doing well with significant decrease of the tumor at 60 months (Fig. 3C, D) . Case 3: A 61-year-old woman experienced loss of consciousness for 5 minutes when she fell down because of amblyopia while cooking on January 11, 2006. MR imaging revealed a 25 × 25 × 20-mm mass with a large cyst in the suprasellar region. The clinical diagnosis was craniopharyngioma because of the cyst and calcification. The patient was referred to the Nagoya Radiosurgery Center for gamma knife radiosurgery because she had refused surgical treatment. She was persuaded to accept neurosurgery for evacuation of the cyst and pathological diagnosis of the tumor. The tumor was partially removed with cyst evacuation by frontotemporal craniotomy on February 22, 2006 , with the diagnosis of lymphoplasmacytic meningioma based on frozen section examination. The final diagnosis was chordoid glioma based on the histochemical findings. She experienced slight disorientation, memory disturbance, and impairment of higher neural functions after surgery. Intensive rehabilitation of neural and mental functions was necessary from April to June 2006 for recovery from the symptoms. Finally, she came back to the Nagoya Radiosurgery Center to have the residual tumor treated by gamma knife radiosurgery performed on June 22, 2006 with a marginal dose of 12 Gy, and dose to the optic nerves of less than 10 Gy (Fig. 2C) . One year and one
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month after the gamma knife surgery, the patient accidentally died during bathing, although the tumor size was slightly decreased at 5 months, and she had been doing well after the treatment.
Histological examination found the tumors consisted of clusters and cords of oval to polygonal epithelioid-shaped cells with eosinophilic cytoplasms, embedded in a mucinous matrix (Fig. 4A ). Mitoses were rare and necrosis was absent. Lymphoplasmacytic infiltrates were found in all tumors (Fig. 4B) . Immunohistochemically, chordoid glioma was strongly and diffusely positive for GFAP and vimentin in all cases (Fig. 5A, B) , and showed focal reactivity to EMA and cytokeratin in some cases. Little or no reactivity was found to S-100 protein in Case 2 (Fig. 5C ). Neurofilament protein was positive only rarely in Case 3 (Fig. 5D ).
Discussion
Chordoid glioma of the third ventricle is considered to be a benign glial tumor with distinct pathological and clinical features, included in the grade II category of the WHO classification of tumors of the central nervous system. 3, 9) Pathologically, the tumor consists of clusters and cords of oval to polygonal epithelioid-shaped cells with eosinophilic cytoplasms, which are embedded in a mucinous matrix. Mitoses are rare and necrosis is absent. Lymphoplasmacytic infiltrates and Russell bodies are often found in the tumor. 1, 2, 4, 6, 11, 15, 17, 18, 21, 24, 25, [27] [28] [29] [30] [32] [33] [34] 36) Immunohistochemically, chordoid glioma is strongly and diffusely positive for GFAP and vimentin, and shows focal reactivity to EMA and cytokeratin in some cases, but little or no reactivity to S-100 protein. Some authors reported immunoreactivity for CD34, 4, 12, 15, 17, 18, 21, 24, 25, 27, 28, 30, 31, [33] [34] [35] [36] which will be useful for making differential diagnoses from chordoid meningioma, pilocytic astrocytoma, and/or ependymoma. 21) The MIB-1 index has been low in all reported cases, ranging from 0% to 5%. Chordoid gliomas are thought to be negative for synaptophysin or neurofilament 8) ; but some cases showed positivity for neurofilament protein as in our Case 3. 4, 10, 16) These findings may suggest that both neuronal and glial differentiation occurs.
The histogenesis of chordoid glioma remains uncertain. 3, 31) The immunohistochemical positivity for GFAP and vimentin favors glial origin. Two recent reports suggested that this tumor was of subcommissural origin based on ultrastructural findings. 8, 28) Electron microscopy findings are also suggestive of glial origin, especially of ependymal cells known as tanycytes located in the anterior third ventricle. 19, 23, 33) A case of coexistence of chordoid glioma and Rathke's cleft cyst may suggest origin from multipotential stem cells of Rathke's pouch. 34) Clinical diagnosis of chordoid glioma has been made by routine imaging techniques using computed tomography (CT) and MR imaging. The characteristic MR imaging findings are an isointense ovoid or round mass on T 1 -weighted and a slightly hyperintense mass on T 2 -weighted images, with homogeneous enhancement by gadolinium. 29, 37) Most tumors are solid, but some cystic area is present in 25% of cases. CT will be helpful for detecting any abnormal calcification present. Our Case 1 was solid, and Cases 2 and 3 had cysts around the solid masses. Case 3 showed calcification, suggesting the clinical diagnosis of craniopharyngioma. Differential diagnosis is necessary with suprasellar tumors such as craniopharyngioma, hypothalamic gliomas, hypothalamic hamartoma, germ cell tumors, central neurocytoma, malignant lymphoma, colloid cyst, or papilloma of the choroid plexus. Pathological differentiation from ventricular meningioma is important because the initial pathological diagnoses of the three cases were all meningioma.
Initial presentations of chordoid glioma vary from asymptomatic or incidental detection 12) to aggressive behaviors, 10, 18, 38) although most cases show slow and mild progression. Presenting symptoms may be headache and vomiting, visual disturbances, fatigue, gait difficulties, memory or consciousness disturbances, urinary incontinence, hyperphagia, weight gain, or psychosis. These symptoms are due to intracranial hypertension caused by hydrocephalus and/or local signs of the optic pathways, fornices, and hypothalamus.
Clinical outcomes of chordoid glioma have been poor, despite the low-grade histological features. 10, 18, 21) Among 54 of 55 patients treated by surgery, 27 had gross total removal (GTR), 22 had partial removal (PR), and 5 cases were biopsied. No recurrence was reported for a long duration after GTR, 5, 8, 12, 28, 39) but five patients (22.7%) had recurrence after PR. GTR carries significant risk because of the close relationship between the tumor and the critical organs nearby. Twenty patients died (74%) over a mean duration of 10.2 months, of which 12 were postoperative (44.4%) and 8 were due to tumor recurrence. The most frequent cause of death was pulmonary embolism (42%), most likely due to hypothalamic dysfunction. 24, 30) Other fatal complications were pneumonia, bacterial meningitis, septicemia, and cardiac arrest. 17, 21, 24, 38) Nonfatal but serious morbidity was often found after surgical removal. 18, 26, 39) Diabetes insipidus, 3, 14, 34) hypotension and hyponatremia, 21, 25) hypothermic episodes, 39) weight gain, 28) and memory disturbance and psychotic changes 3, 16, 26, 28, 31) were reported.
Additional or adjuvant radiation therapy was performed in 10 cases after PR or biopsy and 3 died of tumor recurrence. Conventional radiotherapy was given in 4 cases, 3, 14, 37) and two died of recurrence. Two patients survived for 4 years and for 9 months, one of whom received focal radiotherapy of 52 Gy with additional stereotactic radiosurgery of 20 Gy. 37) Two patients underwent additional interstitial radiotherapy to the residual tumor. 21) One patient survived for 15 months but the other died after 11 months from recurrence. Recently, three patients were treated with gamma knife radiosurgery after PR of tumor. Gamma knife radiosurgery was first used for a residual tumor after subtotal removal in 1999. 31) Although the patient survived for 3.5 years without recurrence, no description of the radiation dose or the outcome was made available. Two other patients had no recurrence; one for a year 16) and the other for 2 years. 24) The results of gamma T. Kobayashi et al.
knife radiosurgery seemed better than those from other radiation modalities, and all treated patients had no recurrence. Another case was the same as our Case 3. 16) The patient died accidentally 13 months after gamma knife radiosurgery, although the patient had been doing well. The cause of death was speculated to be epileptic attack, but autopsy was not performed. In our three cases, GTR was not treated because of the associated high morbidity and mortality. Two cases underwent biopsy (Cases 1 and 2) and the third case had PR followed by gamma knife radiosurgery with a lower dose. The timing of gamma knife radiosurgery was 2-4 months after surgery. At the last follow up, two patients have been living productive lives, surviving for 70 and 66 months without morbidity, and serial MR imaging showed the tumors were well controlled.
The present results suggested that patients with chordoid glioma of the third ventricle treated with stereotactic radiosurgery for residual tumor after biopsy or PR have a strong chance of long survival with control of the tumor without major morbidity such as radiation optic neuropathy. 22) However, to obtain the best result, the optimal radiation dose and tumor size for gamma knife radiosurgery should be determined. Residual tumor (4 × 4 × 3 cm) after PR was treated with a relatively high marginal dose of 15-18 Gy. 24) The patient was survived for 2 years after treatment, but hypothalamic and pulmonary disturbances occurred. Another case of PR was followed by focal radiotherapy of 52 Gy with additional stereotactic radiosurgery of 20 Gy to the residual tumor. 37) No information was available on the outcome of the patient after such a high-dose treatment.
Excellent results of gamma knife radiosurgery were also obtained with cases of low grade optic and hypothalamic glioma using similar low dose treatment. 20) The ideal treatment for chordoid glioma would be GTR without complications, but this is quite difficult because of the size and location of the tumor. 8, 13, 17, 27, 31) PR can reduce the tumor volume and also increase the distance from the optic pathways, where the risk of morbidity could be minimized while the effect of gamma knife radiosurgery is maximized. Less invasive microsurgery and gamma knife radiosurgery with a lower marginal dose can provide a safe and effective treatment for chordoid glioma of the third ventricle.
